Uncontrolled cell proliferation is a fundamental feature of cancer. Normal cells maintain the homeostasis of cell proliferation by regulating the cell cycle and division, whereas cancer cells deregulate these signals and become masters of their destiny. Glucose metabolism reprogramming can meet the energy requirements and biological macromolecular requirements for the rapid proliferation of cancer cells. At the same time, glucose metabolism-related enzymes have regulatory effects on cell cycle and cell proliferation signaling pathways. CD BioGlyco enables the use of omics techniques to analyze the interaction mechanism between glucose metabolism reprogramming and cancer cell proliferation.
Fig. 1 The relationship between metabolic enzymes and the cell cycle (Icard P, et al., 2019)
Cell proliferation consists of three components, namely growth, DNA replication, and cell division, which are all manifested in the cell cycle progression, so cell proliferation is achieved through the cell cycle. The cell cycle is regulated by cyclin-dependent kinases, and the expression of cyclin-dependent kinases is regulated by the energy supply of glucose metabolism, and glucose metabolism-related enzymes have non-metabolic functions to maintain cancer cell proliferation. Therefore, we are able to provide the following specific services, including but not limited to:
Cell proliferation is inseparable from cell signaling. In normal cells, extracellular stimulation is required to initiate signaling, however, cancer cells generally do not require extracellular stimulation and are able to escape normal physiological constraints to maintain rapid cell proliferation. We are able to provide mechanistic analysis between cell signaling and glucose metabolism based on the MOPCGM platform.
We can analyze specific proliferative signaling pathways associated with the regulation of glucose metabolism in cancer cells as follows:
CD BioGlyco can analyze the regulatory role of glucose metabolism reprogramming in cell cycle and key cell proliferation signaling pathways based on the MOPCGM platform. Our experienced teams of scientists, researchers, and technicians provide a fast turnaround, and high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.